IMNM

Immunome, Inc.

Healthcare
Biotechnology
$2.36B market cap

Forecast run · Sep 14, 2026Upside rank 1213 of 3,136

Model Signal

ForecastQ Daily Probabilities

41.1%

23.4%

21.8%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$24.67

Price target$35.25

Implied move+42.9%

Analysts13

ForecastQ Portfolios

IMNM is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.